GANX241018C2000
- 0.40
- 0.000.00%
Gain Therapeutics Newsroom
Gain Therapeutics Announced The Presentation Of New Evidence Supporting The Disease-modifying Activity Of Gt-02287 In Preclinical Animal Models Of Both GBA-1 And Idiopathic Parkinson's Disease
Gain Therapeutics to Participate at Upcoming Investor Conferences
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
BTIG Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $10
Gain Therapeutics Shares Are Trading Lower. The Company Announced the Presentation of a Late-breaking Abstract at the International Congress of Parkinson's Disease and Movement Disorders.
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
12 Health Care Stocks Moving In Friday's After-Market Session
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $5
Maxim Group analyst Jason McCarthy maintains $Gain Therapeutics(GANX.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 24.9%
Optimistic Buy Rating for Gain Therapeutics' GT-02287 Based on Promising Parkinson's Disease Treatment Potential
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024
Express News | Gain Therapeutics Inc Files for Common Stock Offering of up to $50 Mln - SEC Filing
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Announces Target Price $5
Maxim Group analyst Jason McCarthy maintains $Gain Therapeutics(GANX.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 26.1% and a
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Ram Selvaraju maintains $Gain Therapeutics(GANX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 43.0%
Oppenheimer Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
Oppenheimer analyst Jay Olson maintains $Gain Therapeutics(GANX.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 42.0% and a
Small-Cap Gain Therapeutics Stock Falls On Phase 1 Data From Its Lead Asset For Parkinson's Disease
Gain Therapeutics Shares Are Trading Lower. The Company Announced Positive From the Phase 1 Study Conducted to Evaluate the Safety, Tolerability and Pharmacokinetics of GT-02287.